Close menu




November 25th, 2021 | 12:44 CET

BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?

  • Biotechnology
Photo credits: pixabay.com

The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".

time to read: 2 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Cardiol Therapeutics: Get in now after successful capital increase?

    In addition to vaccines, drugs are the great hope for getting the Corona pandemic under control. So far, there is no approved drug with proven efficacy. Cardiol Therapeutics (Cardiol) is researching such a drug for COVID-19 patients and has reached an important milestone. The US FDA approved the treatment of hospitalized COVID-19 patients with CardiolRX, Cardiol's main product, as part of a clinical study. The Canadian Company is also researching a compound related to acute myocarditis and regeneration of the heart muscle. Currently, this is in phase 2.

    It is well known that research costs money. Nevertheless, Cardiol's recent capital increase caught investors on the wrong foot. Although the issuance was placed within a few hours and the Company received about USD 50 million, the share price dropped significantly and is currently quoted at CAD 2.60. As a result, the share has lost around 50% of its value within 4 weeks. However, progress is being made in drug development. According to the experts at GBC Research, this is a good time to buy. Following the capital increase, the analyst house from Augsburg has again recommended the Cardiol share as a buy. The experts believe study results for the COVID-19 drug will be released in the fourth quarter of 2021 or the first quarter of 2022. GBC's price target for the Cardiol share is CAD 17.49, considerably higher than the current price.

    Valneva: Recovery after the Flash Crash?

    The Valneva share caused astonishment on Tuesday. Within less than half an hour, the share price plummeted from over EUR 21 to as low as EUR 17.66. But there was positive news. Valneva and the EU Commission signed the contract for the supply of Valneva's COVID-19 vaccine VLA2001. According to the agreement, the French Company is to supply 24.3 million doses of the vaccine in the second and third quarters of 2022. A total of up to 60 million doses are to be supplied in 2022 and 2023. The prerequisite is that the vaccine is approved. Study results published to date have been positive. Many hopes rest on VLA2001 to increase the vaccination rate in Germany and other countries. This is because it is an inactivated vaccine. The vaccine is based on the virus in its natural form, which is chemically inactivated and cannot reproduce in the vaccinated person's body. However, upon contact, the body reacts with the same immune response as the active coronavirus and forms antibodies.

    BioNTech: Boosters and compulsory vaccinations drive the share price up

    Things are currently going well at BioNTech. The share has left its correction behind and is once again setting its sights on the EUR 300 mark. Booster vaccinations are picking up speed. In Germany alone, Health Minister Jens Spahn had to order additional doses. Demand has risen insanely in the past two weeks, Spahn said, and they will deliver 6 million BioNTech doses starting this week alone. But there is more good news for BioNTech. Because soon, children as young as five could also be vaccinated in Europe. Today, the European Medicines Agency (EMA) is expected to decide whether to approve BioNTech's vaccine for children in this age group. So far, there is no Corona vaccine approved for children under the age of twelve in the EU. This mixed situation should give the BioNTech share further impetus.


    COVID-19 continues to keep the world busy. Vaccine manufacturers like BioNTech and Valneva are benefiting. Effective drugs will also become cash cows, and Cardiol is going full throttle to develop one.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read